Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.562
Peer-review started: August 29, 2016
First decision: November 21, 2016
Revised: January 25, 2017
Accepted: March 21, 2017
Article in press: March 21, 2017
Published online: April 18, 2017
Positron emission tomography computed tomography (PET-CT) using 18-Fluoro-deoxyglucose (18FDG) is an imaging modality that reflects cellular glucose metabolism. Most cancers show an uptake of 18FDG and benign tumors do not usually behave in such a way. The authors report herein the case of a 38-year-old female patient with a past medical history of cervical intraepithelial neoplasia and pheochromocytoma, in whom a liver lesion had been detected with PET-CT. The tumor was laparoscopically resected and the diagnosis of inflammatory hepatic adenoma was confirmed. This is the first description of an inflammatory hepatic adenoma with an 18FDG up-take.
Core tip: In cancer therapy, the use of 18-Fluoro-deoxyglucose (18FDG) positron emission tomography computed tomography as a staging or prognostic tool, is increasing. This is also the case for primary or secondary liver cancer. In this paper, the authors report the first description of an inflammatory hepatic adenoma with 18FDG uptake.